Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nursing ethics

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Nursing ethics. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-003866-14 Sponsor Protocol Number: B5091007 Start Date*: 2017-06-15
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older
    Medical condition: Primary C difficile infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    20.0 10021881 - Infections and infestations 10012748 Diarrhoea, Clostridium difficile LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BG (Completed) SE (Completed) HU (Completed) BE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) FI (Completed) PT (Completed) ES (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001384-23 Sponsor Protocol Number: REG1-CLIN310 Start Date*: 2013-10-30
    Sponsor Name:Regado Biosciences, Inc.
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTI-CENTER, ACTIVE-CONTROLLED, PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF THE REG1 ANTICOAGULATION SYSTEM COMPARED TO BIVALIRUDIN IN PATIENTS UNDERGOIN...
    Medical condition: Coronary Artery Disease (CAD) in patients undergoing Percutaneous Coronary Intervention (PCI)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10011085 Ischaemic coronary artery disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) EE (Prematurely Ended) DE (Prematurely Ended) NL (Completed) PT (Prematurely Ended) AT (Completed) GB (Completed) IT (Prematurely Ended) BE (Completed) SK (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004352-33 Sponsor Protocol Number: ALLN-177-301 Start Date*: 2018-07-18
    Sponsor Name:Allena Pharmaceuticals, Inc.
    Full Title: Evaluate the Safety and Efficacy of ALLN-177 in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study
    Medical condition: Enteric Hyperoxaluria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004552-64 Sponsor Protocol Number: 131016 Start Date*: 2017-07-03
    Sponsor Name:Center for Digestive Diseases, Karolinska University Hospital
    Full Title: MISTRAL - Mistletoe therapy in primary and recurrent inoperable pancreatic cancer - A phase III prospective, randomized, double blinded, multicenter, parallel group, placebo controlled clinical tr...
    Medical condition: Primary or recurrent inoperable pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001642-10 Sponsor Protocol Number: SMT19969/C005 Start Date*: 2019-03-13
    Sponsor Name:Summit (Oxford) Limited
    Full Title: A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment ...
    Medical condition: Clostridium difficile infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed) LT (Completed) BE (Prematurely Ended) DE (Completed) CZ (Completed) ES (Ongoing) FR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2011-004800-40 Sponsor Protocol Number: AT1001-041 Start Date*: 2012-01-25
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: An Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects with Fabry Disease.
    Medical condition: Fabry disease is a rare X-linked lysosomal storage disorder caused by mutations in the gene (GLA) that encodes the lysosomal enzyme α-galactosidase A.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed) DK (Completed) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001641-27 Sponsor Protocol Number: SMT19969/C004 Start Date*: 2019-07-05
    Sponsor Name:Summit (Oxford) Limited
    Full Title: A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment ...
    Medical condition: Clostridium difficile infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GR (Prematurely Ended) BG (Completed) ES (Ongoing) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-003547-38 Sponsor Protocol Number: ALLN-177-206 Start Date*: 2018-07-17
    Sponsor Name:Allena Pharmaceuticals, Inc.
    Full Title: Pilot Study of ALLN-177 in Adult and Pediatric Subjects Aged 12 Years or Older with Enteric or Primary Hyperoxaluria and Hyperoxalemia
    Medical condition: Enteric or primary hyperoxaluria and hyperoxalemia
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000568-41 Sponsor Protocol Number: GS-US-417-0301 Start Date*: 2016-10-11
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to ...
    Medical condition: Moderately to severely active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) GB (Completed) BE (Completed) HU (Completed) CZ (Completed) DE (Completed) ES (Completed) BG (Completed) PL (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002701-38 Sponsor Protocol Number: AT1001-042 Start Date*: 2014-12-17
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: An Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in subjects with Fabry Disease
    Medical condition: Fabry disease is a rare X-linked lysosomal storage disorder caused by mutations in the gene (GLA) that encodes the lysosomal enzyme a-galactosidase A.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) GB (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-003109-28 Sponsor Protocol Number: ICLA-20-PNE1 Start Date*: 2007-09-28
    Sponsor Name:Arpida AG
    Full Title: Randomized, double-blind, multicenter study to evaluate efficacy and safety of intravenous iclaprim versus vancomycin in the treatment of hospital-acquired, ventilator-associated, or health-care-as...
    Medical condition: Hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), or health-care-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10035664 Pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Prematurely Ended) LT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001048-73 Sponsor Protocol Number: BAY41-6551/13084 Start Date*: 2013-07-25
    Sponsor Name:Bayer AG
    Full Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Pati...
    Medical condition: Gram-negative pneumonia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10035701 Pneumonia gram-negative bacterial NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-018374-20 Sponsor Protocol Number: 6517-CL-0020 Start Date*: 2010-12-09
    Sponsor Name:Cardiome UK Limited
    Full Title: A Phase 3b Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Vernakalant Hydrochloride Injection in Patients with Recent Onset Symptomatic At...
    Medical condition: Recent Onset Symptomatic Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002360-30 Sponsor Protocol Number: NA-1-009 Start Date*: 2021-01-05
    Sponsor Name:NoNO Inc.
    Full Title: A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Nerinetide in Participants with Acute Ischemic Stroke Under...
    Medical condition: Acute ischemic stroke (AIS)
    Disease: Version SOC Term Classification Code Term Level
    22.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    22.1 10029205 - Nervous system disorders 10055221 Ischemic stroke LLT
    22.1 10029205 - Nervous system disorders 10023027 Ischaemic stroke NOS LLT
    22.1 10029205 - Nervous system disorders 10074321 Nonhaemorrhagic stroke LLT
    22.1 10029205 - Nervous system disorders 10074318 Nonhemorrhagic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Prematurely Ended) IT (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000914-76 Sponsor Protocol Number: 1409R2121 Start Date*: 2014-11-24
    Sponsor Name:Shionogi Inc.
    Full Title: A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Unc...
    Medical condition: Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis caused by Gram-negative Pathogens
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10046577 Urinary tract infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) IT (Completed) ES (Completed) DE (Completed) PL (Completed) RO (Completed) HR (Completed) LV (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-011799-31 Sponsor Protocol Number: DIM19 Start Date*: 2009-10-02
    Sponsor Name:Medivation, Inc
    Full Title: CONTACT: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Six-Month Safety and Efficacy Study of Dimebon in Patients with Moderate-to-Severe Alzheimer’s Disease and Neuropsychiat...
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IE (Completed) ES (Completed) PT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003627-38 Sponsor Protocol Number: H3M116477 Start Date*: 2013-01-30
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) CZ (Completed) BG (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000921-29 Sponsor Protocol Number: ALLN-177-302 Start Date*: 2019-11-12
    Sponsor Name:Allena Pharmaceuticals, Inc.
    Full Title: Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2)
    Medical condition: Enteric Hyperoxaluria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) PT (Completed) ES (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-001485-17 Sponsor Protocol Number: GS-US-432-4097 Start Date*: 2017-08-15
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects with Active Non-Infectious Uveitis
    Medical condition: Non-infectious Uveitis
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004853 10022557 Intermediate uveitis LLT
    20.1 100000004862 10036370 Posterior uveitis LLT
    20.0 100000004853 10033687 Panuveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2005-006083-57 Sponsor Protocol Number: CA184-025 Start Date*: 2006-10-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010) Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols Revised Protocol...
    Medical condition: Stage III, IV metastatic advanced melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) CZ (Completed) DE (Prematurely Ended) AT (Completed) HU (Completed) FI (Completed) SE (Completed) IT (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 12:11:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA